Analysts/Institutional Investor Meet/Con. Call Updates

National Stock Exchange of lndia Limited, Exchange Plaza, C 1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400051, Maharashtra. SYMBOL: QMSMEDI Sub: Transcript of Earning Call for quarter ended June 30, 2026. Dear Sir/Ma’am, We enclose herewith a copy of the transcript of the Earning Call for the quarter ended June 30, 2026 held on August 17, 2026. The same is also being made available on the Company’s website at: https://qmsmas.com/ Kindly take the same on your records and oblige. Thanking you, Yours sincerely, For QMS MEDICAL ALLIED SERVICES LIMITED TORAL JAILESH BHADRA (MEMBERSHIP NUMBER: A56927) (COMPANY SECRETARY AND COMPLIANCE OFFICER) DATE: AUGUST 21, 2026 PLACE: MUMBAI CIN: L33309MH2017PLC299748; Email Id: mm@qmsmas.com “QMS Medical Allied Services Limited Q1 & FY27 Earnings Conference Call” August 17, 2026 MANAGEMENT: MR. MAHESH MAKHIJA – CHAIRMAN AND MANAGING DIRECTOR – QMS MEDICAL ALLIED SERVICES LIMITED MR. MOHIT TAMHANKAR – DIRECTOR, COMPLIANCE – QMS MEDICAL ALLIED SERVICES LIMITED Page 1 of 14 QMS Medical Allied Services Limited August 17, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Q1 FY '27 Earnings Conference Call for QMS Medical Allied Services Limited. The management will be sharing the key operating and financial highlights for the quarter ended June 30, 2026, followed by a question-and-answer session. Please note that some of the statements made in today's discussion may be forward-looking in nature and may involve risks and uncertainties. Documents relating to the company's financial performance are available on the stock exchange and the company's website. Trust, you have been able to go through the same. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. I now hand the conference over to Mr. Mahesh Makhija, Chairman and Managing Director. Thank you, and over to you, sir. Mahesh Makhija: Thank you. Good afternoon, everyone. This is Mahesh Makhija, Chairman and Managing Director of QMS Medical Allied Services, and I'm delighted to welcome you all to the Quarter 1 FY '27 Earnings Conference Call of QMS Medical Allied Services. Our financial results and investor presentation has been uploaded on stock exchange as well as on our website. And I hope you had an opportunity to review them. Joining me on our call today is Mr. Mohit Tamhankar, he is our Director Compliance. It gives me immense pleasure to share our quarter 1 FY '27 performance with you. This quarter marks a strong start to the new financial year and comes on the back of several important milestones of QMS. One of the key milestones was our successful migration of the SME platform to the main board of NSE on June 18, 2026. This reflects the progress we have made over the years and reinforces our commitment to ending a larger, stronger and more diversified health care services platform. For the next few minutes, I'll take you through the industry landscape of our business performance and our financial results of Q1 FY '27. India healthcare industry continues to offer a strong long-term growth opportunities supported by rising healthcare awareness, increase in healthcare spending, expanding access to health care and the rapid adoption of digital health solution. At the same time, the growing burden of chronic diseases and increasing treatment complexity advising greater focus on continued patient care, adherence, and engagement. Against this backdrop, the patient service programs of PSP ecosystem is gaining increasing importance. Pharmaceutical companies are increasingly moving beyond medicines towards more holistic patient-centric care. PSP typically focus on treatment, access, patient education, adherence, disease management and on on-going patient engagements, particularly across chronic and specialty therapies. Indian pharmaceutical industry provides a large and expanding ecosystem for PSP. India is also a major global supplier of medicines accounting for around one-fifth of the global generic Page 2 of 14 QMS Medical Allied Services Limited August 17, 2026 medicine supply. As pharmaceutical companies increasingly focused on improving patient access, adherence and outcomes we expect demand for our integrated and technology-enabled PSP platform to continue growing. We believe that the combination of both the on-ground execution, digital engagement and data- driven patient support present some meaningful long-term opportunity for QMS. Coming to our performance, I'm pleased to report that we have started FY '27 on a strong growth. Our consolidated revenues from the operations stood at INR56.9 crores, registering a 22% year-on- year growth. More importantly, our EBITDA grew faster than revenue, increasing 27% year on to INR8.3 crores with the EBITDA margin improving 14.6% compared with 14.1% in Q1 FY '26 and 13.3% in the Q4 FY '26. PAT stood at around INR4 crores, growing 25% year-on-year. While our PAT margins have improved to 7%, the sequential performance is equally increasing. The revenue increased by 28%. Quarter-on-quarter EBITDA grew by 41% and PAT more than doubled, increasing 110% over quarter 4 FY '26. I believe these numbers are particularly important because they demonstrate that the investments we made during the FY '26 in people, technology, infrastructure and service capabilities are now beginning to translate into a strong revenue growth and improved operational performance. As the business continues to result around two complementary pillars, product and services. Our Product business continued to see a healthy traction during the quarter across our healthcare and wellness portfolio, including Q-Devices. We are strengthening our presence across multiple channels, including the pharmaceutical companies, hospitals, clinics, QMeds, our ePortal, eGramin, and our digital platforms. Our expanding distribution network and a broad product portfolio basis a strong foundation to scale this business further. We will continue our focus on expanding our own brand portfolio, strengthening our distribution network and increasing our presence across our point of care and other health care segments. At the same time, our services business is emerging as an increasingly important growth engine for QMS The business has been driven by a deeper pharmaceutical partnerships increasing adoption of patient support programs and the growing scale of our health care camp operations. During our quarter 1 FY '27, our PSP business, including subsidiary, Saarathi Healthcare generated approximately INR17 crores of revenue. We currently hold a 76% stake in Saarathi Healthcare and are progressing towards acquiring the remaining stake, which we expect to complete by the end of quarter 2 FY '27. This will further strengthen our capabilities in disease management and the patient support program, enabling us to address the patient journey in a more comprehensive manner. Today, our proprietary technology platform supports 100-plus programs and more than 1 million patients providing real brand tracking, monitoring, analytics and patient engagement capabilities. This combination of technology health care expertise and on-ground execution gives us the ability to manage patient programs at a larger scale. Our B2B health care camps also continues to scale during this quarter. Page 3 of 14 QMS Medical Allied Services Limited August 17, 2026 We are very pleased to announce that we have conducted more than 11,497 B2B health camps in the Quarter 1 FY '27 demonstrating the depth of our field execution capabilities and the trust based on us by our profitable factors. Importantly, we see PSP and healthcare camps as complementary capabilities. Camps enable screening, awareness and early diagnosis while PSP grows us to engage that mak [Showing first 8,000 characters — download PDF for full document]